Search Results - hcc

5 Results

Sort By:

High-Affinity Mouse Monoclonal Antibodies to GPC-3 for Liver Cancer Research

Abstract: The National Cancer Institute Laboratory of Molecular Biology seeks parties for collaborative research to co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics. There is great interest and value in developing more sensitive and efficient agents for earlier detection of hepatocellular cancer (HCC). ...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Yen Phung, Wei Gao, Yifan Zhang

Keywords(s): ANTIBODY, GLYCOPROTEIN, Glypican-3, GPC3, HCC, hepatocellular carcinoma, liver, monoclonal

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma

Abstract: Early detection of liver cancer, such as hepatocellular carcinoma (HCC), is key to improve cancer-related mortality. More than 800,000 people are diagnosed with this cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 700,000 deaths each year. Currently, millions...

Published: 4/8/2024 | Inventor(s): Xin Wei Wang, Jinping Liu, Wei Tang

Keywords(s): Biomarker, HCC, hepatocellular carcinoma, Liver cancer, viral infection, Wang

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Diagnostics

Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma

Abstract: The National Cancer Institute seeks parties to license human monoclonal antibodies and immunoconjugates and co-develop, evaluate, and/or commercialize large-scale antibody production and hepatocellular carcinoma (HCC) xenograft mouse models. An advantage of these monoclonal antibodies as a potential therapeutic is their specificity, which...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Mingqian Feng, Dimiter Dimitrov, Heungnam Kim, Wei Gao

Keywords(s): Antibody-drug Conjugate, chimeric antigen receptor, HCC, hepatocellular carcinoma, IMMUNOTOXINS, Liver cancer

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Gene Signature for Predicting Solid Tumors Patient Prognosis

Abstract: HCC is the most frequent malignant tumor in the liver and the third leading cause of cancer death worldwide. A progressive sequence of somatic mutations and epigenetic changes of oncogenes or tumor suppressor genes are believed to cause tumor development. However, high genomic instability in tumors causes the accumulation of genomic aberrations...

Published: 4/8/2024 | Inventor(s): Xin Wei Wang, Stephanie Roessler

Keywords(s): Biomarker, driver gene, gene signature, HCC, hepatocellular carcinoma, prognostic

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Oncology

Combination of recombinant IL-7 with Chimeric Antigen Receptor (CAR) T Cells Targeting Glypican-3 (GPC3) for the Treatment of Hepatocellular Carcinoma (HCC)

Abstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. standard treatment for HCC is not suitable for a large proportion of liver cancer patients. As a result, alternative treatments are needed. Chimeric antigen receptor (CAR) T cell therapy is a promising alternative approach selectively targets targeting tumors via tumor-specific...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Dan Li, Byung Ha Lee, Sara Ferrando-Martinez

Keywords(s): CAR, Chimeric Antigen Receptor T Cell Therapy, Glypican-3, GPC-3, HCC, hepatocellular carcinoma, HO, Interleukin-7, liver, Recombinant IL-7, Tumor Specific Antigen

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Therapeutics